Gurugram (Haryana) [India], October 8 (ANI/PRNewswire): Premas Biotech, developer of technologies & bioprocesses for novel proteins, today announced that Oravax Medical Inc., a US-based company that Premas Biotech is a shareholder in, reported positive preliminary data from its Phase 1 trial in South Africa of an oral Covid-19 vaccine candidate. Preliminary Phase 1 trial results from the first cohort include: - Significant antibody response (2-6 fold over baseline) as measured by multiple markers of immune response to VLP vaccine antigens observed in the majority of the patients dosed - was observed in 75 per cent of the patients dosed - No safety issues were observed, including mild symptoms Oravax Medical is a clinical-stage vaccine company developing oral vaccines that combine Premas Biotech's D-Crypt Platform with Oramed Pharmaceuticals' POD technology. Oravax's oral Covid-19 vaccine candidate is designed using D-Crypt technology as a triple antigen VLP vaccine that